Eli Lilly: Novo Nordisk Was Just A Warm-Up

Novo Nordisk (NOVO) is no longer viewed as a near-term threat, leaving Lilly's (LLY) Tirzepatide to dominate the injectable obesity and Type 2 Diabetes markets for ~1.5-2 years. I expect Foundayo to capture massive global maintenance and "Overweight" markets with >$20B in 2030 sales. Retatrutide is set to monopolize the high-margin Class III Obesity (BMI >40) market, with no direct triple-agonist competition expected until around 2031.